Posters

Intravitreal injection is a biomechanical model for evaluation of glaucoma pathophysiology

Poster Details

First Author: I.Bubnova RUSSIA

Co Author(s):    M. Budzinskaya   A. Kurguzova                 

Abstract Details

Purpose:

Study of influence of transitional acute IOP rise after intravitreal injection (IVI) anti-VEGF drug on the structures of anterior and posterior segments of eye globe.

Setting:

Prospective cohort study was conducted in research Institute of eye diseases, Moscow, RF.

Methods:

Study was performed on random sample, consisting of 40 patients (40 eyes) aged 63 – 81 with age-related “wet” form of AMD. According to medical indications all the patients received intravitreal injection of ranibizumab 0,05 ml (Novartis). IOP was measured by contact spot tonometry ICare® PRO (IСare, Finland). Structures of anterior segment were evaluated by Scheimpflug system (Pentacam HR). Changes of optic nerve head configuration such as optic cup width, optic cup depth, Bruch’s membrane opening (BMO), lamina cribrosa depth (LCD) were assessed by optical coherent tomography (Spectralis OCT). All measurements were done before IVI, after 15 and 30 minutes.

Results:

IOP max rise was determined on average to 38 mm Hg (30÷45 mm Hg, p<0,05). Increase of values of corneal thickness by 27 µm (14÷38 µm, p<0,041) as well as parameters of optical density of the cornea - by 16,7 (10,4÷19,5, p<0,039) was registered. The enlargement both cup widening (from 22 µm to 38 µm (P=0.001)) and deepening (from 13 µm to 19 µm (P=0.005)) after the IVI was revealed. Whereas BMO and LCD didn’t change. In 30 minutes after both intravitreal injections IOP self-normalization as well as restoration of corneal structure and optic head nerve configuration was observed.

Conclusions:

The results revealed can serve as biomechanical model for study of pathophisiological glaucoma changes of structures of anterior and posterior eye segments in conditions of acute IOP rise. In the future it would interesting to analyze such changes after multiple injections, especially in patients with glaucoma, taking into consideration already existing glaucoma neuropathy in them.

Financial Disclosure:

None